Opus Genetics is trading 6.83% up in pre-market at $4.38, versus October 14 close of $4.10; conference data may be a catalyst, but attribution is unconfirmed.
- Retina in Rio featured OPGx-BEST1 data on October 14; earlier updates cited positive Cohort 1 results and FDA alignment on potential pivotal-trial endpoints.
- All five Cohort 1 participants showed meaningful visual-function improvement, with no serious adverse events or dose-limiting toxicities; mixed market signals do not clearly explain the gain.